The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Targeting menin: A paradigm shift in acute myeloid leukemia therapy
Steering committee meeting
In August, 2026, the AML Hub held a steering committee meeting where Joshua Zeidner presented on Targeting menin: A paradigm shift in acute myeloid leukemia therapy, followed by a panel discussion.
This podcast is independently supported by Kura Oncology. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
1 Jul 2026
FLT3 inhibitors in AML: Current clinical landscape and key insights from trials
The AML Hub was pleased to speak with Mark J. Levis, Johns Hopkins University, Baltimore, US. We asked, What is the current clinical landscape of FLT3 inhibitors in the treatment of AML, and what insights have been gained from trials so far?
Levis provides an overview of the key FLT3 inhibitors in clinical development for the treatment of FLT3-mutated (FLT3m) AML and discusses ongoing questions, including how to select the most appropriate FLT3 inhibitor for different patient populations and how best to incorporate them into standard treatment regimens. He highlights the value of measurable residual disease (MRD) in monitoring disease status as an important insight from clinical trials.
This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
30 Jun 2026
Future directions for FLT3 inhibitors in AML treatment
The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What might the future hold for the evolution of FLT3 inhibitors in the treatment of AML?
Stein summarizes the approved indications for currently available FLT3 inhibitors and considers potential future directions for their investigation in the treatment of acute myeloid leukemia (AML), including in combination regimens and in patients with FLT3-ITD-negative AML.
This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Who has been a guest on AML Hub
Names identified in recent episode analyses. Showing up to five guests.
Gail J Roboz
Ralph Hills
Charles Craddock
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
597,144
Score snapshot 15 Sept 2025
Podcast Authority Score: 37 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
27
Social presence
0
YouTube
86
Engagement
30
Host of AML Hub?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
